CATALOGO DEI PRODOTTI DELLA RICERCA

MILELLA, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.570
EU - Europa 13.962
AS - Asia 11.360
SA - Sud America 1.798
AF - Africa 393
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 42.137
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.159
RU - Federazione Russa 6.336
SG - Singapore 4.848
CN - Cina 2.606
IT - Italia 1.926
BR - Brasile 1.426
GB - Regno Unito 1.145
HK - Hong Kong 1.117
VN - Vietnam 1.063
DE - Germania 944
FR - Francia 905
IE - Irlanda 725
SE - Svezia 598
FI - Finlandia 505
KR - Corea 385
BD - Bangladesh 298
CA - Canada 227
NL - Olanda 219
IN - India 216
ID - Indonesia 207
AR - Argentina 124
JP - Giappone 113
PL - Polonia 112
MX - Messico 107
ES - Italia 104
UA - Ucraina 104
AT - Austria 94
ZA - Sudafrica 84
TR - Turchia 73
IQ - Iraq 71
EC - Ecuador 54
BJ - Benin 53
CO - Colombia 51
TG - Togo 51
NG - Nigeria 49
VE - Venezuela 43
AU - Australia 40
CZ - Repubblica Ceca 39
PK - Pakistan 39
EG - Egitto 30
MA - Marocco 30
UZ - Uzbekistan 30
SA - Arabia Saudita 28
TH - Thailandia 28
CL - Cile 27
IR - Iran 25
PY - Paraguay 25
BE - Belgio 23
CH - Svizzera 23
JO - Giordania 23
LT - Lituania 22
TN - Tunisia 22
MY - Malesia 21
AE - Emirati Arabi Uniti 20
UY - Uruguay 20
PH - Filippine 19
PE - Perù 18
NP - Nepal 17
KZ - Kazakistan 14
DZ - Algeria 13
KE - Kenya 13
AZ - Azerbaigian 12
CR - Costa Rica 12
HR - Croazia 12
KG - Kirghizistan 12
LV - Lettonia 11
PT - Portogallo 11
SN - Senegal 11
IL - Israele 10
JM - Giamaica 10
RO - Romania 10
RS - Serbia 10
AM - Armenia 9
DO - Repubblica Dominicana 9
GR - Grecia 9
HN - Honduras 9
SK - Slovacchia (Repubblica Slovacca) 9
GT - Guatemala 8
AL - Albania 7
AO - Angola 7
BO - Bolivia 7
BY - Bielorussia 7
CY - Cipro 7
DK - Danimarca 7
EU - Europa 7
LU - Lussemburgo 7
NO - Norvegia 7
PS - Palestinian Territory 7
TW - Taiwan 7
BG - Bulgaria 6
ET - Etiopia 6
MK - Macedonia 6
PA - Panama 6
KH - Cambogia 5
SI - Slovenia 5
SY - Repubblica araba siriana 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
HU - Ungheria 4
LA - Repubblica Popolare Democratica del Laos 4
Totale 42.058
Salva come PNG Salva come JPEG
Città #
Singapore 2.464
Ashburn 2.106
Moscow 2.052
Dallas 1.811
San Jose 1.751
Chandler 1.265
Hong Kong 1.101
Verona 790
Southend 738
Dublin 697
Council Bluffs 531
Beijing 501
The Dalles 443
Ho Chi Minh City 351
Munich 346
Woodbridge 334
New York 319
Jacksonville 305
Los Angeles 297
Lawrence 267
Princeton 267
Hanoi 225
Helsinki 205
Ann Arbor 197
Houston 197
Sindelfingen 185
Buffalo 170
Jakarta 155
São Paulo 153
Redondo Beach 150
Milan 149
Redmond 139
Wilmington 137
Jinan 136
Santa Clara 130
London 124
Tokyo 98
Turku 91
Frankfurt am Main 87
Nanjing 84
Orem 83
Shenyang 83
Columbus 81
Montreal 80
Chicago 75
Nuremberg 74
Toronto 74
Lappeenranta 72
Tianjin 69
Amsterdam 68
Warsaw 68
Seattle 64
Hebei 61
Da Nang 58
Meda 58
Johannesburg 57
Atlanta 56
Cotonou 53
Brooklyn 52
Lomé 51
Chennai 49
Guangzhou 49
San Francisco 48
Rome 47
Ningbo 46
Stockholm 46
Vienna 46
Abuja 45
Changsha 45
Rio de Janeiro 45
Seoul 45
Denver 44
Zhengzhou 40
Belo Horizonte 39
Haiphong 37
Boardman 36
Hangzhou 36
Poplar 36
Boston 35
Mumbai 35
Mexico City 33
Paris 33
Washington 33
Shanghai 32
Haikou 31
Kent 31
Nanchang 31
Baghdad 30
Barnet 30
Falkenstein 30
Phoenix 30
Taiyuan 30
Bologna 29
Dong Ket 29
Biên Hòa 28
Tashkent 28
Ankara 26
Curitiba 26
Madrid 26
Taizhou 26
Totale 24.326
Salva come PNG Salva come JPEG
Nome #
Assessment of Psychological Burden in Individuals with Hereditary Risk of Pancreatic Cancer Under Surveillance: Evaluation of Distress 3 Years After Enrollment 335
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 312
Genomic characterization of hepatoid tumors: context matters 261
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 254
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 250
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models 216
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 216
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 213
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 209
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma 204
Long-Term Survivor of Intrahepatic Cholangiocarcinoma for over 18 Years: Case Study with Longitudinal Histo-molecular and Tumor Immune Microenvironment Characterization and Systematic Review of the Literature 201
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 201
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 200
Acinar Cystic Transformation of the Pancreas: Histomorphology and Molecular Analysis to Unravel its Heterogeneous Nature 199
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 199
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 199
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 196
Sex differences in oncogenic mutational processes 195
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 194
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 192
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 192
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 191
A multimodal approach to cancer-related cachexia: from theory to practice 191
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 186
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 185
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 184
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer 184
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 181
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 181
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 180
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss 178
ERK 1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 177
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 176
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 176
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 175
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 174
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar 174
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 173
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 173
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen 172
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 169
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 169
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 168
Loss of FGFR4 promotes the malignant phenotype of PDAC 166
Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis 166
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 165
Do immune checkpoint inhibitors need new studies methodology? 164
Exercise levels and preferences in cancer patients: a cross-sectional study 164
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 164
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 163
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma 163
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 162
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 161
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 161
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 161
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 160
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 160
Treatment of locally advanced rectal cancer in the era of total neoadjuvant therapy: a systematic review and network meta-analysis 160
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 160
A cross-sectional study exploring the perception of exercise oncology in the Italian population 159
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 157
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 157
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 157
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 157
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 156
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions 156
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 156
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 155
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 155
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 155
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 155
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 155
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial 155
Pan-cancer analysis of whole genomes 154
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 153
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 152
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 152
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 152
Muscle derangement and alteration of the nutritional machinery in NSCLC 151
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 150
A Journey through the Multifaceted Landscape of Prostate Cancer: from Bench to Bedside Studies 150
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 149
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 149
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 149
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 149
Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites 147
Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients 146
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias 146
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 146
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 146
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 145
Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization 145
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 145
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 145
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 144
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona 144
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 144
Case report: Male genital system, soft tissue and myocardial metastases in a patient with exon 11-mutated GIST of unknown origin 144
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 143
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 142
Totale 17.322
Salva come PNG Salva come JPEG
Categoria #
all - tutte 162.022
article - articoli 160.602
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 357
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.063
Totale 324.044
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202171 0 0 0 0 0 0 0 0 0 0 0 71
2021/20221.789 110 378 60 108 46 22 37 103 59 37 310 519
2022/20234.070 290 364 383 714 323 1.057 61 223 440 49 105 61
2023/20242.607 91 167 234 360 225 356 206 191 56 126 419 176
2024/20257.962 438 354 332 1.393 349 302 437 439 1.112 629 730 1.447
2025/202623.191 1.501 1.258 2.031 3.586 5.544 1.347 2.020 1.367 1.845 1.366 566 760
Totale 42.694